Recent news
November 2010
Biotechnology investors and executives discuss research incentives and financing
November 3, 2010 -- Biotechnology executives and investors gathered last week at the annual Mid-Atlantic Bio Conference, hosted by the Virginia Biotechnology Association, the Mid-Atlantic Venture Association, and the Tech Council of Maryland. During the conference, panelists discussed some of the challenges associated with attracting investors to biotechnology and ways to overcome these challenges, including finding new sources of funding or accelerating the US Food and Drug Administration (FDA) approval process. James Greenwood, president and chief executive of the Biotechnology Industry Organization, and John Castellani, president and chief executive of the Pharmaceutical Research and Manufacturers of America, said that tax credits and reduced capital gains taxes could foster investment in research. In addition, Joshua Sharfstein, the FDA's principal deputy commissioner, said that regulatory science "really needs to grow in concert with biomedical research" so that a balance is found between breakthrough medicines and safety. See the links below for more details.
